GIGAGEN

In News

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B - Contagion Live

Contagion Live - Nov 25, 2024

GigaGen doses first subject in Phase I advanced solid tumour trial - Clinical Trials Arena

Clinical Trials Arena - May 21, 2024

Grifols' GigaGen garners up to $135M from BARDA to tackle botulinum biothreat - Fierce Biotech

Fierce Biotech - Oct 03, 2024

Exploring The Future of HBV Treatment with GigaGen GIGA-2339 - The Clinical Trial Vanguard

The Clinical Trial Vanguard - Aug 21, 2024

GigaGen teams with NCI to develop oncology drug candidate - BioProcess International

BioProcess International - Feb 29, 2024

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant - GlobeNewswire

GlobeNewswire - Oct 03, 2024

Unleashing the potential of lab-grown recombinant polyclonal antibodies - Drug Target Review

Drug Target Review - Jul 17, 2024

Recombinant polyclonal antibodies for viral diseases - Drug Discovery News

Drug Discovery News - Mar 26, 2024

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development - finance.yahoo.com

finance.yahoo.com - May 19, 2022

GigaGen's New Contract with BARDA for Polyclonal Antibody Development - Contagion Live

Contagion Live - Oct 04, 2024

GigaGen Expands Contract With US Department of Defense for Synthetic Antibody Treatments for Botulinum Neurotoxins - Infection Control Today

Infection Control Today - Nov 27, 2023

Phase 1 clinical trial cleared for HBV antibody GIGA-2339 - European AIDS Treatment Group

European AIDS Treatment Group - Aug 07, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment